February 4, 2013
Authors Shaun Kumar (1,2), Ash Kaur (1,2), Carl Kirkpatrick (3), John Ray (2), Brian Egan (2), Daniel Bradshaw (4), Gary Graham (1,2), Kenneth Williams (1,2), Gail Mathews (4), Richard Day (1,2)
Affiliations 1. School of Medical Sciences, University of New South Wales, 2. Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Darlinghurst, 3. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 4. Department of Immunology B Ambulatory Care, St Vincent's Hospital, Darlinghurst
Presentation type Poster
Presenters Shaun Kumar
Background: Dual therapy of ribavirin and pegalated interferon is the first line therapy for Hepatitis C. Ribavirin has a narrow therapeutic index with high plasma concentrations resulting in haemolytic anaemia. The aim of ribavirin therapy is to reduce serum viral load whilst minimizing side effects. Strategies such as dosing on body weight or according to […]
